Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice.

We describe a tolerance-based stem cell transplantation protocol that combines sublethal radiation with transient blockade of the CD40-CD154 costimulatory pathway using an anti-CD154 antibody. With this protocol, we established hematopoietic chimerism in BALB/c mice transplanted with fully allogeneic C57BL/6 bone marrow. The percentage of donor-origin mononuclear cells in recipients was more than 99%. In addition, all chimeric mice treated with anti-CD154 antibody remained free of graft-versus-host disease (GVHD) and accepted donor-origin but not third-party skin allografts. It was similarly possible to create allogeneic hematopoietic chimerism in NOD/Lt mice with spontaneous autoimmune diabetes. Pancreatic islet allografts transplanted into chimeric NOD/Lt mice were resistant not only to allorejection but also to recurrence of autoimmunity. We conclude that it is possible to establish robust allogeneic hematopoietic chimerism in sublethally irradiated mice without subsequent GVHD by blocking the CD40-CD154 costimulatory pathway using as few as 2 injections of anti-CD154 antibody. We also conclude that chimerism created in this way generates donor-specific allograft tolerance and reverses the predisposition to recurrent autoimmune diabetes in NOD/Lt mice, enabling them to accept curative islet allografts. (Blood. 2000;95:2175-2182)

[1]  C. Kaufman,et al.  Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. , 1995, Surgery.

[2]  D. Waite,et al.  Ontogeny and immunohistochemical localization of thymus-dependent and thymus-independent RT6+ cells in the rat. , 1996, The American journal of pathology.

[3]  B. Woda,et al.  Immunopathology of diabetes in the RT6-depleted diabetes-resistant BB/Wor rat. , 1990, The American journal of pathology.

[4]  A. Michael,et al.  Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. , 1984, Transactions of the Association of American Physicians.

[5]  M. Sykes,et al.  Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance , 1998, The Journal of experimental medicine.

[6]  C. Larsen,et al.  The CD40 pathway in allograft rejection, acceptance, and tolerance. , 1997, Current opinion in immunology.

[7]  R. Owen.  IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS. , 1945, Science.

[8]  C. Mathieu,et al.  Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved. , 1997, Journal of immunology.

[9]  C. Kaufman,et al.  Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow. , 1997, Journal of immunology.

[10]  G. Szot,et al.  Separate regulation of peripheral hematopoietic and thymic engraftment. , 1998, Experimental hematology.

[11]  B. Woda,et al.  NOD mice have a generalized defect in their response to transplantation tolerance induction. , 1999, Diabetes.

[12]  M. Sykes,et al.  Mixed hematopoietic chimerism and transplantation tolerance , 1997, Immunologic research.

[13]  J. Gribben,et al.  Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.

[14]  V. Farewell,et al.  Using and Understanding Medical Statistics , 1984 .

[15]  G. Warnock,et al.  Prevention of Recurrence of IDDM in Islet-Transplanted Diabetic NOD Mice by Adjuvant Immunotherapy , 1992, Diabetes.

[16]  Kaizhai Shen,et al.  CD4 , 1990 .

[17]  W. Silvers,et al.  Importance of chimerism in maintaining tolerance of skin allografts in mice. , 1973, Journal of immunology.

[18]  S. Boggs,et al.  Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. , 1996, Journal of immunology.

[19]  R. Flavell,et al.  Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. , 1999, Journal of immunology.

[20]  R. Burt,et al.  Hematopoietic stem cell therapy of autoimmune diseases. , 1998, Current opinion in hematology.

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[22]  I. Stamenkovic,et al.  A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Greiner,et al.  Autoimmune Destruction of Islets Transplanted Into RT6-Depleted Diabetes-Resistant BB/Wor Rats , 1990, Diabetes.

[24]  R. Noelle,et al.  Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. , 1997, Transplantation.

[25]  Y. Colson,et al.  Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts. , 1995, Transplantation.

[26]  S. Ildstad,et al.  Bone marrow transplantation for therapy in autoimmune disease , 1997, Stem cells.

[27]  D. Greiner,et al.  Recapitulation of normal and abnormal BioBreeding rat T cell development in adult thymus organ culture. , 1999, Journal of immunology.

[28]  D. Harlan,et al.  Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. , 1999, Diabetes.

[29]  D. Greiner,et al.  Induction of immunologic tolerance for transplantation. , 1999, Physiological reviews.

[30]  K. Lafferty,et al.  The role of CD 4 ' and CD 8 ' T cells in the . destruction of islet grafts by spontaneously diabetic mice ( nonobese diabetic mice / diabetes / transplantation / autoimmumty ) , 2022 .

[31]  R. Noelle,et al.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. , 1998, The Journal of clinical investigation.

[32]  D. Greiner,et al.  High frequency apoptosis of recent thymic emigrants in the liver of lymphopenic diabetes-prone BioBreeding rats. , 1998, Journal of immunology.

[33]  R. Flavell,et al.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.

[34]  K. Sullivan,et al.  The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. , 1997, The Journal of rheumatology. Supplement.

[35]  A. Aruffo,et al.  The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. , 1993, Journal of immunology.

[36]  W. Silvers,et al.  The abolition of tolerance of skin homografts in rats with isoantiserum. , 1970, Journal of immunology.

[37]  T. Strom,et al.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. , 1999, Journal of immunology.

[38]  R. Schwartz.  The new immunology--the end of immunosuppressive drug therapy? , 1999, The New England journal of medicine.

[39]  R. Noelle,et al.  Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Harlan,et al.  Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates , 1999, Nature Medicine.

[41]  E. Jantunen,et al.  Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives , 2000, Bone Marrow Transplantation.

[42]  J Wagner,et al.  The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation , 1998, Bone Marrow Transplantation.

[43]  K. Sullivan,et al.  Autologous stem cell transplantation for autoimmune diseases: issues in protocol development. , 1997, The Journal of rheumatology. Supplement.

[44]  D. Sachs,et al.  Mixed allogeneic chimerism as an approach to transplantation tolerance. , 1988, Immunology today.

[45]  D. Greiner,et al.  Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody. , 1999, Transplantation proceedings.

[46]  D. Greiner,et al.  Abnormalities in the export and fate of recent thymic emigrants in diabetes-prone BB/W rats. , 1996, Autoimmunity.

[47]  L. Lu,et al.  Are dendritic cells the key to liver transplant tolerance? , 1999, Immunology today.

[48]  M. Atkinson,et al.  The NOD mouse model of type 1 diabetes: As good as it gets? , 1999, Nature Medicine.

[49]  R. Noelle,et al.  CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. , 1998, The Journal of clinical investigation.

[50]  T. Strom,et al.  Induce Allograft Tolerance with Combined CTLA 4 Signals Are Required to Optimally , 1999 .

[51]  A. Aruffo,et al.  Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. , 1994, The Journal of clinical investigation.

[52]  R. Noelle,et al.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD 154 antibody in thymectomized mice requires CD 4 ( + ) T cells , interferon-gamma , and CTLA 4 , 1998 .